Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. SDCCQ, SSKN, GMVDF, TTOO, and AFIB

Should you buy ViewRay stock or one of its competitors? ViewRay's main competitors and comparable companies include SmileDirectClub (SDCCQ), Strata Skin Sciences (SSKN), G Medical Innovations (GMVDF), T2 Biosystems (TTOO), and Acutus Medical (AFIB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ViewRay compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

SmileDirectClub has higher revenue and earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

In the previous week, SmileDirectClub's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
SmileDirectClub Neutral
ViewRay Neutral

0.1% of SmileDirectClub shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 64.7% of SmileDirectClub shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SmileDirectClub has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
ViewRay N/A N/A N/A

Summary

SmileDirectClub beats ViewRay on 4 of the 6 factors compared between the two stocks.

How does ViewRay compare to Strata Skin Sciences?

Strata Skin Sciences (NASDAQ:SSKN) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Given ViewRay's higher possible upside, analysts plainly believe ViewRay is more favorable than Strata Skin Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Strata Skin Sciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ViewRay
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Strata Skin Sciences has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Strata Skin Sciences$30.98M0.00-$10.09M-$1.41N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

32.4% of Strata Skin Sciences shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 40.9% of Strata Skin Sciences shares are held by company insiders. Comparatively, 2.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ViewRay has a net margin of 0.00% compared to Strata Skin Sciences' net margin of -35.64%. ViewRay's return on equity of 0.00% beat Strata Skin Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Strata Skin Sciences-35.64% -476.73% -33.49%
ViewRay N/A N/A N/A

Strata Skin Sciences has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

In the previous week, Strata Skin Sciences' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Strata Skin Sciences Neutral
ViewRay Neutral

Summary

ViewRay beats Strata Skin Sciences on 7 of the 11 factors compared between the two stocks.

How does ViewRay compare to G Medical Innovations?

ViewRay (NASDAQ:VRAYQ) and G Medical Innovations (NASDAQ:GMVDF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

G Medical Innovations has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
G Medical Innovations$4.42M0.00-$24.63MN/AN/A

ViewRay has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, G Medical Innovations has a beta of 28.66, suggesting that its share price is 2,766% more volatile than the broader market.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 6.0% of G Medical Innovations shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Comparatively, 37.1% of G Medical Innovations shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
G Medical Innovations N/A N/A N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled G Medical Innovations'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
G Medical Innovations Neutral

Summary

G Medical Innovations beats ViewRay on 3 of the 5 factors compared between the two stocks.

How does ViewRay compare to T2 Biosystems?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, T2 Biosystems had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for ViewRay. ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Neutral

ViewRay has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.9, indicating that its stock price is 690% more volatile than the broader market.

T2 Biosystems has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

Summary

T2 Biosystems beats ViewRay on 5 of the 9 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

ViewRay (NASDAQ:VRAYQ) and Acutus Medical (NASDAQ:AFIB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
Acutus Medical -272.74%-311.64%-11.57%

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
Acutus Medical Neutral

ViewRay has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Acutus Medical has a beta of 5.73, meaning that its share price is 473% more volatile than the broader market.

Acutus Medical has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 56.9% of Acutus Medical shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 5.2% of Acutus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ViewRay beats Acutus Medical on 5 of the 9 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16K$5.58B$7.31B$13.29B
Dividend YieldN/A1.79%2.52%12.57%
P/E Ratio0.0025.26274.0825.69
Price / SalesN/A71.56638.2178.99
Price / CashN/A33.0277.8052.76
Price / BookN/A5.7810.476.32
Net Income-$107.33M$151.55M$3.49B$359.73M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A295
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
SSKN
Strata Skin Sciences
N/A$0.01
flat		N/A-99.8%$29K$30.98MN/A120
GMVDF
G Medical Innovations
N/AN/AN/AN/A$26K$4.42MN/A72
TTOO
T2 Biosystems
N/A$0.00
+200.0%		N/A-95.5%$13K$7.68MN/A180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel